{"id":"al8326-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL942","moleculeType":"Small molecule","molecularWeight":"361.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting HDAC enzymes, AL8326 increases acetylation of histone proteins, leading to more open chromatin structure and altered transcription of genes involved in cell cycle arrest and apoptosis. This mechanism is particularly relevant in hematologic malignancies where HDAC inhibition can restore expression of tumor suppressor genes and promote differentiation or death of cancer cells.","oneSentence":"AL8326 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to alter gene expression and induce anti-tumor effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:25.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peripheral T-cell lymphoma (PTCL)"},{"name":"Cutaneous T-cell lymphoma (CTCL)"}]},"trialDetails":[{"nctId":"NCT07392736","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2021-10-26","conditions":"Solid Tumor","enrollment":228},{"nctId":"NCT06794957","phase":"PHASE1","title":"A Study of AL8326 in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2022-05-19","conditions":"Non-small Cell Lung Cancer","enrollment":158},{"nctId":"NCT06247605","phase":"PHASE3","title":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2023-10-26","conditions":"Small Cell Lung Carcinoma","enrollment":243},{"nctId":"NCT05486598","phase":"PHASE1","title":"A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2022-06-21","conditions":"Diet, High-Fat, Pharmacokinetics","enrollment":16},{"nctId":"NCT04890587","phase":"PHASE1","title":"A Phase I Study of AL8326 in Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2017-08-17","conditions":"Advanced Solid Tumors","enrollment":40},{"nctId":"NCT04890795","phase":"PHASE1, PHASE2","title":"A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2020-10-19","conditions":"Small Cell Lung Cancer","enrollment":237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46976,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AL8326"],"phase":"phase_3","status":"active","brandName":"AL8326 tablets","genericName":"AL8326 tablets","companyName":"Advenchen Laboratories Nanjing Ltd.","companyId":"advenchen-laboratories-nanjing-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AL8326 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to alter gene expression and induce anti-tumor effects. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}